Short Interest in Pharming Group (NASDAQ:PHAR) Decreases By 22.3%

Pharming Group (NASDAQ:PHAR) was the target of a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 8,000 shares, a decline of 22.3% from the May 31st total of 10,300 shares. Based on an average daily trading volume, of 4,500 shares, the days-to-cover ratio is presently 1.8 days.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research report on Friday, May 31st.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC acquired a new stake in Pharming Group (NASDAQ:PHAR) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 17,710 shares of the company’s stock, valued at approximately $202,000. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Stock Performance

NASDAQ:PHAR traded up $0.49 during trading hours on Friday, reaching $8.35. 6,777 shares of the company were exchanged, compared to its average volume of 8,333. The stock has a 50 day simple moving average of $9.02 and a 200 day simple moving average of $10.64. Pharming Group has a 52-week low of $6.97 and a 52-week high of $16.71.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.20). The firm had revenue of $55.59 million during the quarter, compared to analyst estimates of $68.43 million. Pharming Group had a negative net margin of 4.01% and a negative return on equity of 4.61%. Analysts expect that Pharming Group will post -0.03 EPS for the current year.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.